Neuland Laboratories reported Q4FY26 total income of ₹788.7 crore, up 134.9% YoY, with PAT surging 666.3% to ₹212.5 crore.
EBITDA margin expanded 2316 bps YoY to 40.5% driven by strong execution and business visibility from commercial molecules.
Management highlighted investments in peptide manufacturing and new R&D centre as groundwork for future sustainable growth.
Company will conduct an earnings call on May 12, 2026, to discuss performance and answer participant questions.